Last reviewed · How we verify
Metisoprinol
At a glance
| Generic name | Metisoprinol |
|---|---|
| Also known as | Isoprinosine |
| Sponsor | Universidad San Francisco de Quito |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial (PHASE3)
- Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 (PHASE3)
- Isoprinosine in HIV Patients With Viral Load > 50 y < 200 Copies/mL (PHASE4)
- A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients (PHASE1)
- A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy (NA)
- A Study of Isoprinosine in Patients With Severe AIDS (NA)
- A Study of Isoprinosine in Patients With Lymph Node Disease (NA)
- The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metisoprinol CI brief — competitive landscape report
- Metisoprinol updates RSS · CI watch RSS
- Universidad San Francisco de Quito portfolio CI